Original Research
Published on 13 Apr 2021
PD-1 Inhibition Enhances Blinatumomab Response in a UCB/PDX Model of Relapsed Pediatric B-Cell Acute Lymphoblastic Leukemia
in Cancer Immunity and Immunotherapy
Frontiers in Oncology
doi 10.3389/fonc.2021.642466
- 9,758 views
- 28 citations

